Recently, the mayor of Rio de Janeiro criticized the pharmaceutical company Novo Nordisk for suggesting ‘term adjustment mechanisms’ for its patents, which could make it difficult to democratize access to the medicine
The mayor of , , is committed to facilitating access to the drug Ozempic, which contains semaglutide, with the expectation that it will be available in the Unified Health System (SUS) from 2026. Recently, Paes criticized the pharmaceutical company Novo Nordisk for suggesting “term adjustment mechanisms” for their patents, which could make it difficult to democratize access to the medicine. To make this initiative viable, Paes formed a working group that will dedicate itself to planning the introduction of semaglutide in family clinics.
“Deadline adjustment mechanisms” are not possible! They have already been more than financially rewarded for the investment made. The time has come to democratize access to this medicine. It can be transformative for the health of Brazilians by reaching SUS!
— Eduardo Paes (@eduardopaes)
The mayor emphasized that it is essential that the population has access to this medicine, especially with the patent breaking scheduled for next year, which will allow production by different manufacturers. The municipal secretary of Health, Daniel Soranz, informed that there are already factories in Brazil preparing to produce Ozempic and that the city hall is in talks with four laboratories, including Novo Nordisk.
Once the program is implemented, doses of semaglutide will be used to treat obesity, requiring medical prescription and follow-up at family clinics.
*Report produced with the help of AI
Published by Fernando Dias
